The study is a single-center, prospective, open-label randomized controlled study. This study evaluates the eligibility rate of different biopsy methods (tubeless tubeless VATS vs. CT guided fine needle aspiration) for the detection of molecular genetic characteristics of peripheral NSCLC next-generation sequencing, and its main purpose is to evaluate the use of tumor gene profiling (NGS) The best biopsy technique, the First Affiliated Hospital of Guangzhou Medical University is the research center. It is expected to be completed between 2021-3-1 and 2023-3-1.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
94
Use uniportal tubeless VATS to obtain the biopsy
Use CT-guided fine needle to obtain the biopsy
Qualified Rate of Biopsy for Second-generation Tibial Specimens
Different biopsy methods (single-port tubeless VATS biopsy vs CT-guided fine-needle aspiration biopsy) are used to evaluate the qualification rate of samples obtained for NGS testing
Time frame: up to 2 years
Progression Free Survival
Progression Free Survival of patients under different biopsy methods
Time frame: up to 2 years
Overall Survival
Overall Survival of patients under different biopsy methods
Time frame: up to 2 years
Tumor Content Size
Tumor Content of patients under different biopsy methods
Time frame: up to 2 years
Gene Mutation Rate
Gene Mutation Rate of patients under different biopsy methods
Time frame: up to 2 years
Drug sensitive mutation detection rate
Drug sensitive mutation detection rate of patients under different biopsy methods
Time frame: up to 2 years
Detection of PD-L1 expression
Detection of PD-L1 expression of patients under different biopsy methods
Time frame: up to 2 years
TMB detection situation
TMB detection situation of patients under different biopsy methods
Time frame: up to 2 years
Correlation between tumor cell content and detection rate of sensitive mutations
Time frame: up to 2 years
Perioperative complications
Time frame: up to 2 years
Postoperative patient experience score
Time frame: up to 2 years
Usage rate of targeted drug
Time frame: up to 2 years
Success rate of enrollment
Time frame: up to 2 years
Postoperative MRD detection
Time frame: up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.